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Abstract: We aimed to create an animal model for hepatocellular carcinoma (HCC) with a short time,
a high survival rate, as well as a high incidence of HCC in both males and females than previously
reported. The Diethylnitrosamine (DEN) model has an age-related effect. A single dose of DEN
treatment is not enough in young mice up to 50 weeks. The same pattern is shown in an adult with
multiple-dose trials whether or not there is some promotion agent. In this study, two-week old
C57BL6 mice were given a total of eight doses of DEN, initially 20mg/kg body weight, and then
30mg/kg in the third week, followed by 50mg/kg for the last six weeks. The first group is DEN
treatment only and the other two groups received thioacetamide (TAA) treatment for four or eight
weeks after one week of rest from the last DEN treatment. An autopsy was performed after 24 weeks
of the initial dose of DEN in each group. The cellular arrangement of HCC in the entire group was
well-differentiated carcinoma and tumor presence with no significant impact on the survival of mice.
Increased levels of the biochemical markers in serum, loss of tissue architecture, hepatocyte death,
and proliferation were highly activated in all tumor-induced groups. This finding demonstrates an
improved strategy to generate an animal model with a high occurrence of tumors combined with
cirrhosis in a short time regardless of sex for researchers who want to investigate liver cancer-related.
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1. Introduction
Hepatocellular carcinoma (HCC) is one of the most aggressive clinical conditions with high
malignancy, quick progression, and poor prognosis [1,2]. Hepatocellular carcinoma is a chronic liver
disease that starts as fibrosis, leads to cirrhosis, and results in cancer. The treatment of hepatocellular
carcinoma is often complex as cirrhosis is the major clinical risk factor associated with 80% of people with
HCC [3], and the potential for surgical resection is limited because of the risk of inducing postoperative
liver failure. Liver transplantation (LT) offers the best chance of long-term survival, but cannot be
offered to all patients because of a shortage of organs [4]. The pathophysiological background of
HCC is still poorly understood. Therefore, it is necessary to identify ideal experimental HCC models
with or without cirrhosis features similar to human HCC. In vivo, experimental models are playing a
significant role in the study of HCC [5]. Genetic, transgenic, or conditional knock-out experimental
models are mainly used in the study of HCC development [6,7]. Numerous chemicals promote HCC
in rodents, of which DEN is most often used to promote cancer development. The application of DEN
at different concentrations and to animals of different ages has variant efficacy and efficiency.
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The simple and effective protocol is a single injection of DEN dosing from 1.25 to 25 mg/kg
body weight using two-week old mice a time at which hepatocytes are still proliferative, resulting
in the appearance of HCC at around 8–12 months [8]. The advantage of chemically induced models,
especially the DEN-induced HCC mouse model, is the resemblance of gene expression patterns to
human HCC poor prognosis class [9,10]. Both DEN-induced tumors and human HCC with poor
prognosis have high proliferation, ubiquitination, and chromosomal instability, as well as low levels of
β-catenin mutation and apoptosis [11]. DEN administration can induce clinical HCC indicators GPC3
and alpha-foetoprotein AFP expression [12,13]. DEN is bioactivated by cytochrome P450, leading to
the formation of mutagenic DNA adducts while also generating reactive oxygen species (ROS) which
damage DNA, oxidative stress, and finally promote hepatocarcinogenesis [14–16]. These protocols are
widely used in the literature and represent a good model to define and investigate primitive HCC
nodules independently from the condition of cirrhosis. Still, the DEN model requires other hallmarks
of human HCC, especially fibrosis in the surrounding microenvironment [17].
Many studies have investigated the development of HCC animal models to reduce the time
and death ratio and to limit the administration of carcinogens. Moreover, reports commonly use
a two-stage model in which a single dose of DEN followed by phenobarbital (PB) is applied as a
promoting agent [18–21]. Although this influences DEN-initiated mice, the effects vary considerably
depending upon gender, age, and strain [8,22,23]. Another two-step hepatocarcinogenesis model
initiated by a hepatocarcinogenic compound followed by partial hepatectomy (PH) induces hepatic
cell proliferation of the liver, which leads to the rapid development of the initiated cells as well as the
rapid occurrence of altered hepatic foci and visible nodules [24,25].
A two-stage model in which the initiation by a genotoxic compound DEN followed by a promotion
phase with non-genotoxic thioacetamide (TAA) is often used for inducing HCC [26]. TAA is bioactivated
by cytochrome P450 enzymes to TAASO and further to TAASO2 with a toxic nature that elevates levels
of reactive oxygen species (ROS), lipid peroxides, cytotoxicity, mitochondrial injury, and glutathione
depletion. Finally, this leads to centrilobular necrosis, apoptosis, and the formation of hepatocellular
carcinoma and cholangiocarcinoma [27]. The treatment with a tumor-promoting agent like TAA has
been shown to induce liver fibrosis development in several different mouse strains, different doses,
administration routes, and treatment durations [26,28–34]. TAA-promotion after initiation with DEN
increased the number and area of hepatocellular foci, numbers of proliferating and apoptotic cells [26].
HCC is a multistep process involving repeated rounds of treatment that lead to inflammation, fibrosis,
and eventually HCC.
One of the issues to make the HCC animal model is the production period and survival rate.
It takes 8–12 months to show carcinogenesis with a high death ratio [35–38]. This is why the appropriate
period is important to make this model mirror the diversity of causes seen in patients such as steatosis,
inflammation, fibrosis, and cirrhosis.
Based on current literature, genotoxic agents like DEN directly induce tumor formation
and, when combined with promoting agents like TAA, enhance both tumor development and
its aggressiveness with fibrosis in the surrounding microenvironment. Taking into consideration the
reproducibility of HCC development, the time required and the survival rate of the animal models are
at potential risk to the investigator. Appropriate animal models are essential to the investigation of
HCC with or without a cirrhotic background and to providing information regarding its molecular,
cellular, and pathophysiological mechanisms, as well as to the development and challenge for the
novel therapeutic processes. Therefore, the present study was conducted to develop a detailed protocol
that appears to be a suitable animal model for HCC after cirrhosis with a short modeling time,
improved survival rate, and increased tumor incidence for researchers who want to use liver cancer
animal models.
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2. Results
2.1. General Observations
Throughout the experimental period, body weight in the control group progressively increased
every time whereas body weight in all treatment groups increased slowly at first, then decreased
after the last injection of DEN which was again slowly recovered after two weeks of the last injection.
During this whole experiment period, one mouse from the DEN and two mice from the DEN+TAA
for 8 weeks treatment group died. The mice whose body weight was more than 5 g at the first DEN
injection time survived until the end of the experiment while mice less than 5 g in body weight died
during the experiment (Figure 1b). As shown in Figure 1c and Table 1, the final body weights were
significantly decreased in all treated groups relative to the mock control group (p < 0.01), while the liver
weights in the treated groups increased (p < 0.01, Figure 1d), which is a common feature of HCC [37,39].
The survival ratio was 97% in the DEN group and 100% in the D+T 4 wks group, while the D+T 8 wks
group showed 85% animal survival until the end of the experiment (Figure 1b).
Figure 1. A tumor development pattern in the animal model. (a) Grouping and schedule. (b) The
survival ratio in all four groups at the end of the experiment. (c) Final body weight for all groups.
(d) Relative liver weight for all groups. (e) Macroscopic view of representative images of mice livers
6 months after DEN administration. Data are presented as means ± SD. ** Significantly different from
the control group (p < 0.01).
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Table 1. Body and liver weight in the animal model.





Control 0 34.3 ± 1.9 1.08 ± 0.13 3.2 ± 0.49
DEN 8 wks DEN 21.9 ± 3.2 * 1.68 ± 0.20 7.7 ± 2.08 *
DEN+TAA 8 wks DEN + TAA 4 wks 22.7 ± 3.1 * 1.8 ± 0.12 8.2 ± 0.94 *
DEN+TAA 8 wks DEN + TAA 8 wks 22.1±0.6 * 1.8 ± 0.15 8.2 ± 0.58 *
* Significantly different from the control group (p < 0.05).
2.2. Liver Tumors
Immediately after sacrifice, the livers were removed, weighed, and the numbers of visible tumors
on the liver surface were counted macroscopically. All animals either male or female treated with
either DEN alone or DEN+TAA for four or eight weeks developed tumors, as shown in Figure 1e
and Supplementary Figures S1 and S2, but the size decreased in the TAA combination group when
compared to the DEN single treatment, which may have been correlated with cirrhosis progression
during tumor development. The overall tumor number was nearly similar in the DEN and D+T 4 wks
group, while it increased in the D+T 8 wks group (Table 2, Supplementary Table S1).
Table 2. Liver tumor incidence.
Group Mice # with Tumor/Total # of Mice Tumor No. Tumor No./Animal
Control 0/13 0 0
DEN 29/29 204 7.2 ± 3.42
DEN + TAA 4 weeks 13/13 106 8.81 ± 0.94 ns
DEN + TAA 8 weeks 11/11 126 11.5 ± 2.76 *
* Significantly different from the DEN group (p < 0.05), ns (not significant).
2.3. Assessment of HCC
The presence of HCC was confirmed by histopathologic examination of the liver sections with
H&E staining. The mock control group showed the normal architecture, whereas the DEN treated
group showed loss of architecture and the presence of tumors (Figure 2a). Some non-tumor areas also
showing numerous huge pathological vacuoles in hepatocytes suggest those lipid droplets accumulated
in the liver and that these animals developed hepatic steatosis (Supplementary Figure S3a). Liver
nodules presented as basophilic foci with crowded nuclei and were classified as a typical HCC
(Supplementary Figure S3b). Adenomas were distinguished from atypical foci based on the presence
of clearly defined margins.
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Figure 2. Liver damage pattern. (a) Representative images of H&E staining from all groups after
6 months of DEN treatment (40×). Black arrows indicate tumors. (b) AST level in serum. (c) ALT
level in serum. values are given as the means ± SD. At least three mice in each group were recorded.
** Significantly different from the control group (p < 0.01).
2.4. Biochemical Markers
The release of alanine aminotransferase and aspartate aminotransferase in serum analyzed which
was used as an indicator of liver injury. The mean serum ALT and AST levels in the DEN-treated group
were three-fold greater than untreated or mock control mice. Mice treated with combination doses of
TAA for further four or eight weeks showed a gradual elevation of ALT and AST serum concentration
respectively. ALT and AST concentrations were statistically significant at all three treated groups
(p < 0.01) (Figure 2b,c).
2.5. Hepatocellular Death and Proliferation
We measured tumor cell proliferation by determining the number of hepatic tumor cells that
were positively immunostained for PCNA in the livers of mice from different groups (Figure 3a,b).
We counted positive stains for proliferating cells, which showed a highly-increased amount of
proliferated cells in all groups relative to mock control mice (p < 0.01). The PCNA positive cells
were scored blind, and 400–700 hepatocytes per field were counted from 6–8 random fields of each
mouse liver with a total of three mice per group. Moreover, the TUNEL apoptosis assay revealed
more apoptotic cells in treated groups relative to the controls (Figure 3b,d). These results suggest that
increased proliferation and cell death occurred in liver tumors during HCC progression.
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Figure 3. DEN-induced tumors show increased DNA proliferation, DNA damage, and apoptosis.
(a) Proliferation in DEN induced HCC models shown in Immunohistochemical staining of PCNA as a
marker for cell proliferation. Scale bar represents 100 µm. (b) Apoptosis in DEN induced HCC models
shown as Immunohistochemical staining of TUNEL as a marker for cell death. In all graphs, the values
presented are relative to controls. Scale bar represents 100 µm. (c) Quantitative analysis for PCNA
positive cell. (d) Quantitative analysis for TUNEL positive cells. In all graphs, the values presented are
relative to controls. Magnification (40× and 400×), values are given as the means ± SD. At least three
mice in each group were recorded. ** Significantly different from the control group (p < 0.01).
2.6. Fibrogenesis
Collagen accumulation is a hallmark of liver fibrogenesis. We first assessed the collagen deposition
by Sirius red staining. Representative images and quantification of Sirius red staining of liver sections
revealed that little collagen was deposited in the livers of control mice or DEN-treated mice, but that
TAA treated mice contained high levels of collagen, especially in the D+T 8 weeks group (Figure 4a,b).
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As expected, the protein expression of collagen 1 (Col1) was generally enhanced in fibrotic/cirrhotic
mice, but the pattern and degree of changes varied among groups (Figure 4c,e). Consistent with the
results of Sirius red staining, a significant increase in collagen 1 was found in groups treated with
additional TAA for four weeks, with peak levels occurring in animals in the eight-week TAA treatment
group (p < 0.01). However, significant differences were observed between the control and DEN treated
groups (Figure 4c,e). Cyclooxygenase (COX)-2, which is also used as an HCC marker, is upregulated
in hepatocellular carcinoma (HCC). Cox2 expression enhanced in DEN treated all groups as compared
to the control group (Figure 4c,d).
Figure 4. Liver cirrhosis pattern. (a) Sirius red staining (200×) for each group. (b) Scoring of the Sirius
red staining. (c) Collagen level and cox2 level by Western blot. β-actin was used as a loading control.
(d,e) Quantitative analysis of collagen and Cox2 normalized with β-actin by the Image J software (NIH).
* Significantly different from the control group (p < 0.05). ** Significantly different from the control
group (p < 0.01).
3. Discussion
Several animal models are commonly used to understand the molecular and cellular basis of
HCC, and DEN is a very common carcinogen used to induce HCC in rodents. The main limitation
of the application of DEN to generate HCC models is the long duration of the experiments. In mice,
most studies employing various methods to accelerate hepatocarcinogenesis have shown that the
average time required for tumor formation is still quite long and tumor incidence is low. Previous
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studies have demonstrated that adult mice treated with DEN did not form tumors for one year [40].
In adult mice, DEN is a weak carcinogen that requires promoting agents such as PB, which may induce
a higher rate of carcinogenesis, but could also modify the characteristics of the tumor slightly as well
as reduce the reproducibility of the model [41,42]. Additionally, the PH-method is based on a difficult
surgical technique and is therefore operator-dependent and less reproducible [24]. Previous findings
suggested that a single DEN dose to infant mice results in efficient HCC induction. Shu et al. reported
that DEN exposure in mice with a C57BL/6 background at the age of 15 days showed 21.4% tumor
incidence at 35 weeks [38]. Another study reported that 45% of mice developed HCC in response to
DEN at 36 weeks [43,44]. Moreover, low-dose (5 µg/g/BW) DEN can cause hepatocellular adenoma at
44 weeks and hepatocellular carcinoma at 68 weeks, with the sequential emergence of preneoplastic
hepatic foci, HCAs, and then HCC [8]. HCC incidence in response to DEN treatment occurs 80–100% in
mice till 105 weeks [45]. Therefore, the present study was conducted to address this gap by generating
a new animal model with a high tumor incidence and low mortality rate that could be utilized within a
short period.
In the long-duration experiment, almost all DEN injected mice died by the time they reached
80 weeks of age, even though they were treated at the age of 14 days with a single DEN dose of
25 mg/kg body weight [38]. In adult mice, a single dose of DEN (200 mg/kg) with combined treatment
of TAA (200mg/kg) for four weeks resulted in a very low survival rate of 20% [37]. In the present
investigation, the survival rate was more than 85% in the entire group until the end of the experiment.
Furthermore, based on our regular two checks every week, there were no clinical signs including
feeding, appearance, behavior, and growth until 24 weeks. The model didn’t have other abnormalities
except for liver cancer at necropsy.
In previous studies of DEN-induced mouse liver cancer, females showed fewer tumors than
males [46], and only 8% of females developed HCC, and males produced 1.6 numbers per mouse [47].
However, in the present study, there were 7.4 tumors per mouse (SD 3.42), and all-female developed
HCC in all treated groups. This may have occurred because DEN doses were administered at an early
age. Interestingly, the mice treated with DEN alone showed significantly larger and greater numbers
of tumors, while treatment with DEN+TAA for four or eight weeks resulted in many small tumors
with a cirrhotic background. H&E staining confirmed microscopic tumor foci in all three groups.
Furthermore, the activity of serum ALT and AST enzymes leakage into the bloodstream indicate the
severity of hepatic damage, [48,49] which is also confirmed in all our treated groups as compared to
untreated control group results.
Recent studies suggest that COX-2 is chronically over-expressed in HCC [50–52]. Clinical studies
indicate that it is an important molecular target for anticancer therapies, and COX-2 inhibitors are
seen to have anticancer effects in HCC [41,42]. In transgenic mice, the overexpression of COX-2
was adequate to induce tumorigenesis [51]. Our study suggests a high level of COX-2 expression
in the DEN group and much more in the DEN+TAA group dose-dependently showing its possible
application as an HCC animal model.
Previous studies have indicated that hepatocyte proliferation and cell death in response
to DEN exposure is associated with apoptosis-induced compensatory proliferation and HCC
development [36,46,53,54]. Similarly, DEN and DEN+TAA treated groups showed a higher number of
proliferating cells, which greater increases observed in the groups treated with DEN+TAA for four
and eight weeks. These results are consistent with those of a human subclass of HCC with poor
prognosis, in which proapoptotic markers were downregulated in response to the upregulation of
proliferating markers in tumors [55]. Overall, the present study provides strong evidence that DEN
alone can cause HCC with a low mortality rate and high tumor incidence in a reduced time compared
to conventional models.
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4. Materials and Methods
4.1. Chemicals
DEN purchased from Sigma-Aldrich (cat# N0756, St. Louis, MO, USA) was freshly dissolved in
0.9% saline and used at various concentrations. Thioacetamide (TAA) from Sigma-Aldrich (cat #172502
St. Louis, MO, USA) was freshly dissolved in phosphate-buffered saline (PBS) before use.
4.2. Animal
In this study, 14.5-day-old C57BL/6 mice were used. The number of total mice in each group is
given in Table 2. All mice were maintained in filter-topped cages on an irradiated regular chow diet
at 22 ± 2 ◦C and 50–60% relative humidity under 12-h light-dark cycles throughout the experiment.
Animal care and all experimental procedures were conducted under the approval and guidelines of the
INHA Institutional Animal Care and Use Committee (INHA IACUC) of the medical school of INHA
University (Approval ID: INHA 160901-435).
4.3. Experimental Design
The mouse body weight of the mice was determined at the time of dosing for the chemical
introduced. A total eight doses of DEN was given in our experiment, the first start dose of DEN was
20 mg/kg body weight, the second dose was 30 mg/kg body and the next six doses were 50 mg/kg body
weight, all of which were injected intraperitoneally (Figure 1a). After one week of rest, an additional
4 or 8 weeks of TAA treatment was administered for the cirrhosis model. Specifically, TAA (300 mg/kg
body weight) was injected twice a week intraperitoneally (Figure 1a). At 3–4 weeks of age, animals
were weaned from their mothers and body weight recorded weekly. Mice were sacrificed at 24 weeks
after the first dose, after which the sera and livers were collected for further analysis
4.4. Histopathological Examination
Immediately after sacrifice, externally visible tumors larger than 0.5 mm were counted by stereo
microscopy. The right lobe was then fixed in 10% formalin and processed for histological examination
by H&E staining, after which it was further examined microscopically for evidence of tumors that
could not be visualized externally.
4.5. Blood Chemistry
Blood was collected by heart puncture at the end of the experiment. Samples were kept at room
temperature for 30 min and then centrifuged at 3000 rpm for 10 min at 4 ◦C, after which the serum
was kept at −80 ◦C until use. Alanine transaminase (ALT) and aspartate aminotransferase (AST) were
determined using the standard protocol.
4.6. Immunohistochemistry
Anti-Proliferative cell nuclear antigen PCNA (sc-56, Santa Cruz, CA, USA) was used for the
quantification of compensatory proliferation on liver section slides, in which at least nine microscope
fields at 40×magnification (3 per group) were examined. Hepatocyte apoptosis was detected using a
TUNEL (TdT-mediated dUTP nick end labeling) ApopTag® Peroxidase In situ Apoptosis detection kit
(Cat# S7100 Merk Millipore, Temecula, CA) following the manufacturer’s instructions. The positive
signals of IHC were measured using the SPOT Software (Version 4.6, Flex 64 Mp mosaic camera).
4.7. Quantification of Fibrosis
Liver sections were stained using a 0.1% PicroSirius red stain kit (ab150681, Abcam Cambridge,
UK) according to the manufacturer’s instructions. The relative fibrotic area, expressed as a percentage
of total liver area, was assessed by analyzing nine fields of the slide per animal. Each field was acquired
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at 20×magnification with the SPOT Software (Version 4.6, Flex 64 Mp mosaic camera). The results
were analyzed using imaging software (Image J, NIH). To evaluate the relative data, the measured
fibrosis area was divided by the net field area and then multiplied by 100.
4.8. Protein Extraction and Western Blot Analysis
Total protein was extracted from the liver (100 mg) using 500 µL lysis buffer [50 mM Tris–HCl
(pH 8.0), 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholic acid, and 1% NP-40
containing protease inhibitors (Protease Inhibitor Cocktail Set I, Calbiochem, San Diego, CA, USA).
The concentration of proteins was determined by bicinchoninic acid (BCA) protein assay (Pierce,
Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instructions. Proteins (20µg/lane)
were separated by SDS–polyacrylamide gel electrophoresis. After electrophoresis, the proteins were
electrotransferred to polyvinylidene fluoride (PVDF) membranes, blocked in 5% non-fat milk for 1 h
at room temperature (RT), and washed with TBST (TBS with 0.1% Tween20), after which they were
probed with anti-col1 (ab63080, Abcam) and Purified Mouse anti-Cox-2 (610203, Becton, Dickinson and
Company, Franklin Lakes, NJ, USA). For these analyses, β-actin (ab8224) served as a loading control
from Abcam (Abcam, Cambridge, UK). Membranes were incubated with appropriate horseradish
peroxidase-conjugated secondary antibody (Cat# sc-2005 Santa Cruz, CA, USA). Each membrane was
developed using an enhanced chemiluminescent substrate for the detection of horseradish peroxidase
(Cat# 32209 Pierce, Thermo Scientific, Rockford, IL, USA), followed by densitometric scanning using
the NIH Image J software version 1.45.
4.9. Data Analysis and Statistics
Statistical analysis was performed using the GraphPad Prism 5 software. Data are expressed as
Means ± SD. A p < 0.05 was considered significant.
5. Conclusion
In conclusion, infant C57BL/6 mice treated with continuous dosing of DEN had a high tumor
incidence after only six months in both genders with an improved survival ratio. Also, the HCC model
of combined liver cirrhosis was successfully established. These models will be useful for future studies
in the field of liver cancer.
6. Patent
Method for preparing hepatocellular carcinoma with liver cirrhosis animal model. Woon Kyu Lee
and Azra Memon, Korea Patent 10-2117590 (2020).
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H&E Hematoxylin and eosin
ALT Alanine transaminase
AST Aspartate aminotransferase
PCNA Proliferating cell nuclear antigen
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling
Col1 Collagen 1
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